相关实验视频
Updated: Jan 16, 2026

07:54
Cholesterol Efflux Assay
Published on: March 6, 2012
30.6K
通过抑制LDLR在肝脏中的表达,ABCC4损害了血LDL胆固醇的清除
Jiaxin Chen1,2, Hui Huang2, Chi Chen2
1Department of Cardiology, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Communications biology
|October 2, 2025
概括
抑制肝细胞载体ABCC4会增加低密度脂蛋白受体 (LDLR) 水平,从而提高LDL胆固醇清除率. 这一发现为高胆固醇血和动脉样硬化提供了新的治疗策略.
科学领域:
- 生物化学 生物化学
- 分子生物学分子生物学
- 遗传学 是一个遗传学.
背景情况:
- 低肝低密度脂蛋白受体 (LDLR) 表达导致高胆固醇血症,这是动脉样硬化心血管疾病 (ASCVD) 的危险因素.
- 鉴定肝脏LDLR的新型调节剂对于开发有效的高胆固醇血症治疗是至关重要的.
研究的目的:
- 通过全基因组CRISPR查,识别肝脏LDLR表达的新型遗传修饰剂.
- 调查针对ABCC4治疗高胆固醇血症和ASCVD的治疗潜力.
主要方法:
- 在肝细胞中进行全基因组的CRISPR/Cas9查,以确定调节LDLR的基因.
- 在细胞模型和雄性小鼠中抑制ABCC4 (肝脏特异性干扰和药理性抑制).
- 对细胞内信号通路 (Epac2/Rap1a) 和蛋白质表达 (PCSK9,LDLR) 的分析.
主要成果:
- 鉴定出ABCC4是肝脏LDLR丰度的关键调节者.
- 抑制ABCC4显著增加了肝脏的LDLR水平,并增强了LDL胆固醇的清除.
- 沉默ABCC4激活了Epac2/Rap1a通路,抑制了PCSK9,并防止了LDLR的溶酶体降解.
- 肝脏特异性的ABCC4干扰和药理抑制降低了小鼠的血LDL胆固醇.
结论:
- 向肝细胞ABCC4代表了高胆固醇血症的有前途的治疗策略.
- 该ABCC4-cAMP-PCSK9-LDLR通路为胆固醇代谢调节提供了新的见解.
- 全基因组的CRISPR查是发现代谢疾病治疗点的强大工具.
相关概念视频
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
1.3K
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.3K
Atherosclerosis III: Management
321
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
321
Cholesterol: Significance and Regulation
1.2K
Although not a source of energy, cholesterol plays a significant role as a foundational structure for bile salts, steroid hormones, and vitamin D, as well as being a crucial component of plasma membranes. Approximately 15% of blood cholesterol is derived from our diet, with the remainder synthesized from acetyl CoA by the liver and intestines. Cholesterol is eliminated from the body through its conversion into bile salts, which are eventually discarded in the feces.
Considering cholesterol and...
Considering cholesterol and...
1.2K
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
214
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
214
Hepatic Drug Clearance: Role of Transporters
297
In the liver and bile canaliculi, influx and efflux transporters modification can influence intrinsic clearance. Transporters play a significant role in moving drugs within liver cells. Elaborate models, such as the Biopharmaceutical Classification System (BCS), are essential to relate transporters to drug disposition. This system categorizes drugs into four classes based on solubility and permeability, providing insights into elimination routes and the effects of transporters following oral...
297
Hepatic Drug Clearance: Restrictive and Nonrestrictive Clearance
478
Hepatic clearance refers to the volume of blood cleared of a drug by the liver per unit of time. It plays a crucial role in drug metabolism and elimination. While hepatic clearance is commonly estimated by subtracting renal clearance from total body clearance, other pathways, such as pulmonary or biliary clearance, may also contribute. However, these pathways are generally less significant than hepatic and renal clearance.
Most drugs undergo restrictive clearance, which is proportional to the...
Most drugs undergo restrictive clearance, which is proportional to the...
478

